【摘要】 目的:观察吉西他滨(健择)联合厄洛替尼(erlotinib,Tarceva)治疗晚期胰腺癌的疗效、临床受益反应和毒性反应。方法:12例晚期胰腺癌患者,均有组织病理学或细胞学诊断及可评价的客观指标。采用健择1000mg/m2,静脉滴注,第1、8、15天,每28天重复,同时联合Tarceva口服150mg/天。结果:12例患者中,有11例可以评价疗效,其中获得CR1例、PR3例,SD3例,总有效率为36.4%,稳定率为27.3%,临床受益反应率为72.7%。主要毒性反应是皮疹、腹泻、口腔炎、白细胞减少、血红蛋白下降、恶心、呕吐和转氨酶轻度升高等。结论:吉西他滨联合厄洛替尼是治疗晚期胰腺癌患者的有效方案,副反应可以耐受。更多还原

【Abstract】 Objective:To evaluate the efficacy,clinical benefitial response(CBR),and toxicity of Tarceva combined with gemcitabine in advanced pancreatic adenocarcinoma. Methods:12 patients were enrolled in this study,with histologically or cytologiaclly confirmed advanced pancreatic adenocarcinoma,all of whom had bidimensionally measurable leisionhs. Gemcitabine was administered as 1 000mg/m~2 weekly for 3 weeks. Tarceva was administered orally 150mg/day. Results:There were 11 of the 12 patients might be evaluated for the objective response. The total response rate was 36.4% ,including 1 CR,3 PR and 3 SD patients,and CBR was 72.7%. The major side effects were rash,diarrhea,inflammation of oral cavity,myelosuppression,and gastrointestinal tract response and slight liver function damage. Conclusion:Tarceva plus gemcitabine is an effective therapy for the patients with advanced pancreatic adenocarcinoma. The efficacy and CBR improved,and the toxicities can be tolerated.更多还原